105 related articles for article (PubMed ID: 1672260)
1. Effectiveness of high-dose MCNU therapy and hematopoietic stem cell autografts treatment of childhood acute leukemia/lymphoma with high-risk features.
Takaue Y; Watanabe T; Hoshi Y; Abe T; Matsunaga K; Saito S; Hirao A; Kawano Y; Ninomiya T; Kuroda Y
Cancer; 1991 Apr; 67(7):1830-7. PubMed ID: 1672260
[TBL] [Abstract][Full Text] [Related]
2. High-dose chemotherapy and blood stem cell autografts for children with first relapsed acute lymphoblastic leukemia: a pilot study of the Children's Cancer and Leukemia Study Group of Japan (CCLSG).
Takaue Y; Watanabe A; Murakami T; Watanabe T; Kawano Y; Kuroda Y; Matsushita T; Kikuta A; Kosaka Y; Kudo T
Med Pediatr Oncol; 1994; 23(1):20-5. PubMed ID: 7909913
[TBL] [Abstract][Full Text] [Related]
3. [Phase II study of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU)].
Tanaka I; Kobayashi T; Shirakawa S; Ikeda Y; Kobayashi M; Yamagata K; Ohta K; Ohno R; Yamada H; Yamada K
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):493-8. PubMed ID: 3859248
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of high-dose ranimustine, cytarabine, etoposide and CY (MCVAC) regimen followed by autologous peripheral blood stem cell transplantation for high-risk diffuse large B-cell lymphoma.
Kato J; Mori T; Yokoyama K; Tsukada Y; Ueda T; Shimizu T; Okamoto S
Bone Marrow Transplant; 2011 Jul; 46(7):923-8. PubMed ID: 20972471
[TBL] [Abstract][Full Text] [Related]
5. A new nitrosourea derivative for the treatment of chronic myelogenous leukemia.
Hiraoka A; Masaoka T; Shibata H; Miyazaki T; Nakamura T; Yasunaga K; Kitani T; Yonezawa T; Kawagoe H; Horiuchi A
Leuk Res; 1988; 12(6):487-90. PubMed ID: 3043111
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of engraftment after cryopreservation of peripheral blood stem cell autografts by controlled- versus uncontrolled-rate methods.
Takaue Y; Abe T; Kawano Y; Suzue T; Saito S; Hirao A; Sato J; Makimoto A; Kawahito M; Watanabe T
Bone Marrow Transplant; 1994 Jun; 13(6):801-4. PubMed ID: 7920317
[TBL] [Abstract][Full Text] [Related]
7. Total body irradiation, thiotepa, and cyclophosphamide as a conditioning regimen for children with acute lymphoblastic leukemia in first or second remission undergoing bone marrow transplantation with HLA-identical siblings.
Zecca M; Pession A; Messina C; Bonetti F; Favre C; Prete A; Cesaro S; Porta F; Mazzarino I; Giorgiani G; Rondelli R; Locatelli F
J Clin Oncol; 1999 Jun; 17(6):1838-46. PubMed ID: 10561223
[TBL] [Abstract][Full Text] [Related]
8. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
9. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
[TBL] [Abstract][Full Text] [Related]
10. [Interstitial pneumonitis following high-dose MCNU].
Shimokawa T; Koyama T; Takaue Y; Watanabe T; Kawano Y; Ninomiya T; Kuroda Y
Gan To Kagaku Ryoho; 1989 Dec; 16(12):3809-11. PubMed ID: 2574565
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of acute lymphoblastic leukemia in adults with seven-drug induction therapy and intensive consolidation with or without autologous stem cell transplantation followed by maintenance therapy. Experience of a single center].
Doubek M; Mayer J; Korístek Z; Protivánková M; Brychtová Y; Oborilová A; Král Z; Klabusay M; Tomíska M; Buchtová I; Vorlícek J
Cas Lek Cesk; 2002 Mar; 141(4):122-6. PubMed ID: 12046256
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity and toxicity of methyl 6-[3-(2-chloroethyl)- 3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside in experimental animals.
Fujimoto S; Tashiro T; Ogawa M
Gan; 1984 Oct; 75(10):937-46. PubMed ID: 6510639
[TBL] [Abstract][Full Text] [Related]
13. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission.
Marks DI; Forman SJ; Blume KG; Pérez WS; Weisdorf DJ; Keating A; Gale RP; Cairo MS; Copelan EA; Horan JT; Lazarus HM; Litzow MR; McCarthy PL; Schultz KR; Smith DD; Trigg ME; Zhang MJ; Horowitz MM
Biol Blood Marrow Transplant; 2006 Apr; 12(4):438-53. PubMed ID: 16545728
[TBL] [Abstract][Full Text] [Related]
14. Beneficial treatment with methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside in a patient with primary myelofibrosis.
Asano Y; Shimokawa M; Okabe H; Sanefuji H; Kato K
Acta Haematol; 1991; 85(2):103-4. PubMed ID: 2024552
[TBL] [Abstract][Full Text] [Related]
15. [High-dose busulfan, VP-16 and ACNU therapy with stem cell transplantation for the treatment of children with acute leukemia].
Ikuta K; Fujioka K; Sumita H; Takahashi H; Sekiguchi H; Kai S; Kajigaya Y; Funabiki T; Sakai H; Matsuyama S
Rinsho Ketsueki; 1993 May; 34(5):636-42. PubMed ID: 8100284
[TBL] [Abstract][Full Text] [Related]
16. [Randomized controlled study of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU) in comparison with busulfan for chronic myelogenous leukemia].
Masaoka T; Kimura K; Miyazaki T; Hirota Y; Nakamura T; Yasunaga K; Ohkubo H; Okamoto Y; Fujitake H; Kitani T
Gan To Kagaku Ryoho; 1985 May; 12(5):1111-8. PubMed ID: 3888116
[TBL] [Abstract][Full Text] [Related]
17. [Peripheral blood stem cell autografts (PBSCT) in the treatment of 30 children with acute leukemias and lymphoma].
Abe T; Takaue Y; Matsunaga K; Saito S; Hirao A; Okamoto Y; Nakanishi J; Watanabe T; Kawano Y; Ninomiya T
Rinsho Ketsueki; 1991 Nov; 32(11):1425-32. PubMed ID: 1758049
[TBL] [Abstract][Full Text] [Related]
18. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
[TBL] [Abstract][Full Text] [Related]
19. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients.
Lee JW; Kang HJ; Kim S; Lee SH; Yu KS; Kim NH; Jang MK; Kim H; Song SH; Park JD; Park KD; Shin HY; Jang IJ; Ahn HS
Biol Blood Marrow Transplant; 2015 Jan; 21(1):190-5. PubMed ID: 25255163
[TBL] [Abstract][Full Text] [Related]
20. Neurotoxicity and pharmacokinetics of ventriculolumbar perfusion of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU) in dogs.
Kochi M; Takaki S; Kuratsu J; Seto H; Kitamura I; Ushio Y
J Neurooncol; 1994; 19(3):239-44. PubMed ID: 7807174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
